Form 4: Director Sells PACS Group Stock Under 10b5-1 Plan

Mark Hancock, a Director and 10% Owner of PACS Group, Inc., reported the sale of common stock totaling 25,304 shares through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Mark Hancock, a Director and significant shareholder (10% owner) of PACS Group, Inc., has reported transactions involving the sale of the company's common stock.
• These sales occurred on July 8, 2026, and July 9, 2026.
• A total of 25,304 shares were sold.
• The sales were executed under a Rule 10b5-1 trading plan, which was adopted on March 11, 2026.
• The weighted average sale price for the July 8th transaction was approximately $45.0689 per share, with individual sales ranging from $45.00 to $45.2861.
• The weighted average sale price for the July 9th transaction was approximately $45.0627 per share, with individual sales ranging from $45.00 to $45.255.
• Following these transactions, Hancock's beneficial ownership of PACS Group common stock is reported as 53,920,512 shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a slightly negative sentiment due to the significant sale of shares by a director, despite being executed under a pre-arranged plan.

Negatives

• Director Mark Hancock sold a significant number of shares (25,304) in PACS Group, Inc.
• The sales represent a reduction in direct beneficial ownership by a key insider.

Risks

• The sale of a large number of shares by a director, even under a 10b5-1 plan, could be interpreted negatively by the market, potentially impacting share price.
• While the plan was in place, the timing of the sales might raise questions about management's confidence in future stock performance.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The Rule 10b5-1 plan indicates pre-determined selling parameters, but the company's future outlook is not discussed within this document.

Management Comments

• The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, is a common event for executives and directors. However, the scale and timing relative to other company news can influence market perception. This filing provides transparency on such transactions for PACS Group, Inc.

Stakeholder Impact

• Shareholders: May view the sale by a director negatively, potentially leading to short-term price pressure, although the 10b5-1 plan mitigates concerns about insider trading.
• Management: The sale by a director could be seen as a signal, though the pre-planned nature is intended to reduce this impact.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• The reporting person may continue to sell shares under the Rule 10b5-1 plan as per its terms.
• The company may provide further updates on insider transactions as they occur.

Key Dates

Recommendation

The filing reports a sale of stock by a director under a Rule 10b5-1 plan. While insider selling can be a negative signal, the pre-arranged nature of the plan suggests it's not necessarily a reflection of current negative sentiment or non-public information. Without further context on the company's performance or the director's reasons for selling, a 'hold' recommendation is prudent, advising investors to monitor future filings and company performance.

Keywords

PACS Group, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Mark Hancock, Director, Beneficial Ownership, SEC Filing